The 2:1 decision by the U.S. Court of Appeals for the Federal Circuit also might set up yet another fight between the highest court of appeal for patents and the U.S. Supreme Court, which forced the Federal Circuit to reconsider Myriad after reversing the lower court on another landmark case this year.

FORBES: D.C. Court Upholds Myriad Breast-Cancer Patents, Snubbing Supreme Court